<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04082975</url>
  </required_header>
  <id_info>
    <org_study_id>NVP-1203_P3</org_study_id>
    <nct_id>NCT04082975</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of NVP-1203 and NVP-1203-R in Patients With Acute Low Back Pain</brief_title>
  <official_title>A Randomized, Double-blind, Active Controlled, Parallel, Multicenter, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of NVP-1203 in Patients With Acute Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navipharm Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navipharm Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety NVP-1203 in patients with
      acute low back pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, active-controlled, parallel, phase 3 study to
      evaluate efficacy and safety of NVP-1203 in patients with acute low back pain.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 24, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in pain intensity assessed by Visual Analogue Scale(VAS)</measure>
    <time_frame>Baseline and Day 7</time_frame>
    <description>Pain intensity is assessed by 100 mm Visual Analogue Scale(VAS) (0 mm = no pain and 100 mm = maximum pain) evaluated from baseline to Day 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pain intensity assessed by Visual Analogue Scale(VAS)</measure>
    <time_frame>Baseline and Day 3</time_frame>
    <description>Pain intensity is assessed by 100 mm Visual Analogue Scale(VAS) (0 mm = no pain and 100 mm = maximum pain) evaluated from baseline to Day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Finger to Floor Distance(FFD)</measure>
    <time_frame>Baseline, Day 3 and Day 7</time_frame>
    <description>FFD is measured by the Investigators who will ask the patients to bend forward and try to touch the floor with the fingers. The distance between the finger to the floor is measured in cm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Oswestry Disability Index(ODI)</measure>
    <time_frame>Baseline, Day 3 and Day 7</time_frame>
    <description>The questionnaire consists of 10 items with each item having 6 answers associated to activities of daily living. The ODI score range is 0 to 100% (low score: minimal disability, high score: bed-bound or exaggerating)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Physician's Global Assessment of Response to Therapy(PGART)</measure>
    <time_frame>Baseline and Day 7</time_frame>
    <description>Physician's response of change after administration is assessed on 5-point rating scales(very poor, poor, no change, good and very good).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Acute Low Back Pain</condition>
  <arm_group>
    <arm_group_label>NVP-1203</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVP-1203-R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1203</intervention_name>
    <description>Oral dose for 7 days</description>
    <arm_group_label>NVP-1203</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1203-R</intervention_name>
    <description>Oral dose for 7 days</description>
    <arm_group_label>NVP-1203-R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1203 placebo</intervention_name>
    <description>Oral dose for 7 days</description>
    <arm_group_label>NVP-1203-R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1203-R placebo</intervention_name>
    <description>Oral dose for 7 days</description>
    <arm_group_label>NVP-1203</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have ability to comprehend the contents of study and before participating
             in trial and have willingness to sign of informed consent in writing

          -  Subjects who have symptom of acute low back pain

        Exclusion Criteria:

          -  Subjects who cannot prohibit anti-inflammatory drug or muscle relaxants during
             clinical trial

          -  Inadequate subject for the clinical trial by the investigator's decision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seong-Hwan Moon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Hwan Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tae Kyun Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wonkwang University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sung Hye Kim</last_name>
    <phone>+82-31-547-9756</phone>
    <email>shkim@navipharm.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyun Ju Choi</last_name>
    <phone>+82-31-292-5436</phone>
    <email>hjchoi@navipharm.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Navipharm</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>16209</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>82 31 547 9756</phone>
      <email>shkim@navipharm.co.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

